Nuvation Bio Inc.
NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor gā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.01
Price+1.65%
$0.13
1Y
Price
Market Cap
$2.738b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-417.4%
EBITDA Margin-425.2%
Net Profit Margin-403.2%
Free Cash Flow MarginRevenue
$26.748m
+239.7%
1y CAGR+79.9%
3y CAGR+59.9%
5y CAGREarnings
-$217.480m
+61.7%
1y CAGR-186.8%
3y CAGR-145.1%
5y CAGREPS
-$0.64
+69.7%
1y CAGR-135.4%
3y CAGR-103.8%
5y CAGRBook Value
$325.882m
$601.561m
Assets$275.679m
Liabilities$10.459m
DebtDebt to Assets
1.7%
-
Debt to EBITDAFree Cash Flow
-$190.248m
-45.7%
1y CAGR-36.0%
3y CAGR-37.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company